Search hospitals > Minnesota > Duluth
Saint Luke's Hospital of Duluth
Claim this profileDuluth, Minnesota 55805
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Prostate Cancer
Conducts research for Cancer
77 reported clinical trials
3 medical researchers
Summary
Saint Luke's Hospital of Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Prostate Cancer, Cancer and other specialties. Saint Luke's Hospital of Duluth is involved with conducting 77 clinical trials across 171 conditions. There are 3 research doctors associated with this hospital, such as Homam Alkaied, Steven R. Bonin, and Scott Mikesell, DO.Area of expertise
1Lung Cancer
Global LeaderStage II
Stage I
Stage IV
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Homam AlkaiedSaint Luke's Hospital of Duluth3 years of reported clinical research
Studies Lung Cancer
Studies Cancer
15 reported clinical trials
27 drugs studied
Steven R. BoninSaint Luke's Hospital of Duluth11 years of reported clinical research
Studies Small Cell Lung Cancer
Studies Breast Cancer
7 reported clinical trials
21 drugs studied
Scott Mikesell, DOSt. Luke's Hospital of Duluth5 years of reported clinical research
Studies Stroke
Studies Atherosclerosis
1 reported clinical trial
2 drugs studied
Clinical Trials running at Saint Luke's Hospital of Duluth
Breast Cancer
Lung Cancer
Cancer
Prostate Cancer
Breast cancer
Colorectal Cancer
Pancreatic Cancer
Bladder Cancer
Multiple Myeloma
Ovarian Cancer
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's Hospital of Duluth?
Saint Luke's Hospital of Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Prostate Cancer, Cancer and other specialties. Saint Luke's Hospital of Duluth is involved with conducting 77 clinical trials across 171 conditions. There are 3 research doctors associated with this hospital, such as Homam Alkaied, Steven R. Bonin, and Scott Mikesell, DO.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.